CAM
AVBP icon

Cormorant Asset Management’s ArriVent BioPharma AVBP Stock Holding History

Cormorant Asset Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-585,462
Closed -$15.6M – 52
2024
Q4 		$15.6M Hold
585,462
– – 0.86% 28
2024
Q3 		$13.8M Buy
585,462
+70,462
+14% +$1.6M 0.73% 34
2024
Q2 		$9.55M Hold
515,000
– – 0.55% 35
2024
Q1 		$9.2M Buy
+515,000
New +$10.4M 0.4% 47

Other funds holding AVBP

HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cormorant Asset Management's AVBP Position: Q1 2025 in Review

Cormorant Asset Management sold out of ArriVent BioPharma (AVBP) in Q1 2025, closing a stake of 585,462 shares — an estimated $15.6M sold.

Cormorant Asset Management first reported a position in AVBP in Q1 2024 and held it in 4 quarters. The position peaked at $15.6M in Q4 2024. 83 funds tracked by Wall St. Rank hold AVBP as of Q1 2025.

  • Cormorant Asset Management reported no remaining ArriVent BioPharma position as of Q1 2025 after selling out during the quarter.
  • Cormorant Asset Management sold 585,462 ArriVent BioPharma shares in Q1 2025, an estimated $15.6M.
  • Cormorant Asset Management first reported a position in ArriVent BioPharma in Q1 2024 and held it in 4 quarters.
  • Cormorant Asset Management's ArriVent BioPharma position peaked at $15.6M in Q4 2024.
  • 83 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2025.

Based on Cormorant Asset Management's 13F filing for Q1 2025, filed 15 May 2025.